Prostate Cancer Drug Linked to Lower Risk of Cognitive Decline

(MedPage Today) — CHICAGO — Patients with advanced prostate cancer treated with enzalutamide (Xtandi) had a significantly greater decline in cognitive function compared with those who received darolutamide (Nubeqa), according to results from…